InvestorsHub Logo
Followers 3
Posts 1270
Boards Moderated 0
Alias Born 06/06/2017

Re: Shawking post# 33899

Tuesday, 08/23/2022 1:33:37 PM

Tuesday, August 23, 2022 1:33:37 PM

Post# of 34588
Delayed? We were promised up to 12 applied R&D programs planned for 2022, so far only one has started, HYPER-H21-4.
KELOWNA, BC / ACCESSWIRE / July 13, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the pending start of its upcoming human nicotine study NIC-H22-1. Lexaria expects to evidence that processing purified nicotine with its patented drug delivery technology, DehydraTECHTM, leads to enhanced oral-tissue absorption and reduced negative experiences.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LEXX News